##########################################################
#  List of patterns to detect disease related outcomes   #
##########################################################

#1
NP{contains: outcome|disease free survival|dfs|overall survival|os|tumor metastasis|prognosis|prognostic|metastasis|senstivity|tumorigenicity|poor survival|invasion|progression|survival|tumorigenesis|pfs|survival|rfs|free survival|relapse|stages?|staging|outcomes?|tumor sizes?|tumor grades?|clonogenicity|sensitivity|resistance}

#2
NP{head: level|response}







##########################################################
#  List of disease related outcomes from DiMeX database  #
##########################################################

outcome
progression-free survival ( PFS )
Genotype-specific survival differences
Survival analysis
ionizing radiation ( IR )- induced apoptotic response
DNA content , phospho-HER2 and PAX2 expression , and rapamycin sensitivity
MRP2 and GSTP1 polymorphisms and chemotherapy response
paclitaxel chemosensitivity or ABCB1 mRNA expression
rs4919510 in pre-miR-608 , with altered recurrence-free survival
pre-prostatectomy PSA level
Overall survival
response , PFS , or KRAS status
The objective response rate
PSA level
EGFR TKIs response
overall survival ( OS ), relapse-free survival ( RFS )
the average IL-6 level and CEA levels
disease-free survival ( DFS ) in breast cancer
significantly poorer PSA-free survival
BC-specific survival analysis
the LEP and LEPR genes , obesity and breast cancer incidence and survival
OS , NSCLC-related survival , and PFS
MDR1 C3435T polymorphism and chemotherapy response
KRAS 3'-untranslated region and survival
overall survival ( OS )
high E-cadherin expression levels
The overall survival time
the DSB response
DNA damage response and apoptotic gene methylation pattern
a shorter progression-free survival ( PFS ) and overall survival ( OS )
PARP activity and PARP-1 protein level
the H63D allele and patient survival
Response rate
The overall median survival time ( MST )
4390A> ; G ( 453AsnSer ) polymorphisms and treatment response, progression-free-survival ( PFS ) overall-survival ( OS )
the MDR1 C3435T and response
PCa survival
poorer PSA-free survival
shorter event-free survival ( EFS ), overall survival ( OS )
size , grade , TNM stage , and survival
the MYCL1 locus and lung cancer patients' survival
Progression-free survival
The average level
shorter progression-free survival ( PFS )
CRC specific survival ( 150 events )
relapse-free survival ( RFS ) and OS
significantly poorer disease-free survival ( DFS ), overall survival ( OS )